Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital...

Area of Science:

• Digital health interventions
• Artificial intelligence in medicine
• Diabetes management

Background:

• Type 2 diabetes (T2D) management can be improved with personalized lifestyle interventions.
• Digital therapeutics (DTx) offer a novel approach to chronic disease management.

Purpose of the Study:

• To evaluate a digital therapeutic (DTx) integrating continuous glucose monitoring (CGM) and AI for personalized lifestyle interventions in T2D.
• To assess the impact of the DTx on glycemic control, body weight, and quality of life.

Main Methods:

• A study involving 118 participants with non-insulin-treated T2D (HbA1c ≥ 6.5%) receiving standard care.
• Participants used the DTx for three months, with pre-post comparisons of clinical endpoints.
• Long-term data from a second use of the DTx was also assessed.

Main Results:

• A 0.67% HbA1c improvement in the complete cohort and a -1.08% HbA1c reduction in poorly controlled patients (HbA1c ≥ 7.0%) after three months (P < .001).
• Therapeutic target range (< 7.0%) increased from 38% to 60%; 33% approached remission (< 6.5%).
• Second-time DTx users showed a -0.76% HbA1c reduction and -6.84 kg weight loss after six months (P < .001).

Conclusions:

• The DTx demonstrates clinically relevant effects on glycemic control and weight reduction in T2D patients.
• The digital solution is effective for both well and poorly controlled diabetes, with single or repeated use.
• This non-pharmacological DTx, integrating CGM biofeedback and AI, represents a significant advancement in T2D management.